BioPharma

Pharmaceutical supply chains are fundamentally evolving as global disruptions, regulatory demands, and patient expectations converge to redefine how drugs reach the market. In today’s environment, pharmaceutical supply chain resilience depends not only on physical infrastructure and traditional logistics but...

With a focus on Adeno-Associated Virus (AAV), the worldwide market for Contract Development and Manufacturing Organizations (CDMMOs) that biomanufacture cell and gene therapies has shown spectacular development, estimated to reach $0.2313 billion in 2022. Based on projections, this market...

It is projected that the market for pharmaceutical contract manufacturing organizations (CMOs) would expand at a compound annual growth rate (CAGR) of 7.29 percent until the year 2028. This rise may be ascribed to the expanded pharmaceutical industry, which...

During the period of time from 2023 to 2029, the global market for cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services is projected to grow at a compound annual growth rate (CAGR) of 17.5%. In 2022,...

Pharmaceutical businesses increasingly outsource their product development and manufacture to Contract Development and manufacture Organizations (CDMOs), which operate in a fragmented sector that is experiencing significant restructuring. However, a lot of CDMOs put their competitiveness at risk by not...

As the two Trump administration drug pricing deals find their place in the books and more that are likely on the way, the U.S. policy environment can very well soon stabilize for many Big Pharma companies. All this puts...

It is well to be noted that in 2025, a minimum of 14 major pharmaceutical companies across the world went ahead and announced plans to broaden their manufacturing presence in the U.S. so as to lessen the supply chain...